Research and possible future brain health treatments
|
|
- Bertina Ward
- 6 years ago
- Views:
Transcription
1 Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1
2 The Roskamp Institute Not for profit biomedical research institute and clinic > 60 staff including Ph.D. scientists, clinicians, Ph.D. students, research associates, technicians, administrative staff and consultants Research targets neurological and neuropsychiatric disorders Funding: National Institutes of Health; Veterans Administration; Department of Defense; Alzheimer s Association; Roskamp Foundation; Pharma; Publicprivate partnerships; Private donations 2
3 Roskamp Institute Programs Roskamp Laboratories Archer Pharmaceuticals - Nilvadipine SRQ Bio Contract Research Roskamp Clinic Neurology clinic Clinical trials Mild Cognitive Impairment, Alzheimer s, Multiple Sclerosis, Migraine, etc. 3
4 Understanding brain health and dementia July 21, 2016 brandi, roskamp institute 4
5 What should I believe? July 21, 2016 brandi, roskamp institute 5
6 The continuum of neurocognitive disease research 3. Treatment of disease and finding a cure 2. Earlier and more accurate diagnosing 1. Prevention, risk factor identification and risk factor modification*** What is the current state of science? July 21, 2016 brandi, roskamp institute 6
7 3. Treatment of disease, finding a cure; Alzheimer s disease Currently only 5 FDA approved drugs 4 drugs came to market between 1996 and 2003 Last drug was approved in 2014, but is a combination of two older drugs No approved drugs work at the disease targets proteins such as amyloid and tau July 21, 2016 brandi, roskamp institute 7
8 Amyloid plaques in brain tissue July 21, 2016 brandi, roskamp institute 8
9 Why has drug development been so slow? Stigma, denial Money Lack of volunteers needed for clinical trials July 21, 2016 brandi, roskamp institute 9
10 Money: Federal funding in billion to cancer 1.2 billion to heart disease 3 billion to HIV/AIDS Only 566 million to Alzheimer s Disease July 21, 2016 brandi, roskamp institute 10
11 Volunteers 70,000 volunteers urgently needed for 150 clinical trials and research studies in the U.S. related to Alzheimer s Disease (National Institute of Aging 2015) July 21, 2016 brandi, roskamp institute 11
12 Clinical trials offer hope for our future Clinical trials are a way to learn if a treatment is effective and safe Most involve drugs and a placebo Very strict laws govern the way clinical trials are conducted July 21, 2016 brandi, roskamp institute 12
13 So Promising advances in Alzheimer s disease treatment Experimental drugs that target specific disease proteins such as beta amyloid, tau, beta secretase Trials ongoing at Roskamp Institute Different uses for older drugs nilvadipine An encouraging Roskamp Institute trial in Europe (NILVAD) July 21, 2016 brandi, roskamp institute 15
14 Nilvadipine, an older drug with a promising new role A blood pressure medication used in Europe Nilvadipine in animal studies was shown to block production of amyloid and increase cortical brain circulation in animal models Phase 3 trials are nearing completion from 9 sites throughout Europe (NILVAD) Data will soon be analyzed, results finalized STAY TUNED!! July 21, 2016 brandi, roskamp institute 16
15 2. Earlier and more accurate diagnosing New imaging techniques an ability to see amyloid buildup on MRI to aid diagnosis IDEAS trial across the US, Roskamp Institute participates Better understanding of Mild Cognitive Impairment Biomarker validation for earlier detection Current study at Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 17
16 1. Prevention and risk factor modification In the absence of disease modifying treatments, risk reduction takes on new meaning Even with new treatments, risk reduction will be a basic strategy Clinical studies are limited regarding specific interventions, but evidence is sufficient to support modifiable risk factors (Baumgart et el: Summary of the evidence on modifiable risk factors..alzheimer s and Dementia 11(2015) ) July 21, 2016 brandi, roskamp institute 18
17 Risk factors Cannot change age, family history and genetic susceptibility July 21, 2016 brandi, roskamp institute 19
18 Risk factors There is sufficient evidence to support associations or linkages between modifiable risk factors and reduction in risk for mild cognitive impairment and dementia July 21, 2016 brandi, roskamp institute 20
19 Cardiovascular risk factors July 21, 2016 brandi, roskamp institute 21
20 Cardiovascular risk factors for cognitive decline Diabetes strong evidence on increased risk of dementia in people with diabetes Mid-life obesity strong evidence for an increased risk of dementia Mid-life hypertension strong evidence for an increased risk of Mild Cognitive Impairment July 21, 2016 brandi, roskamp institute 22
21 Lifestyle factors that reduce risk Stop smoking Physical activity even mild activity is linked to decreased risk of cognitive impairment Diet combined Mediterranean/Dash diet probably has most evidence among diets for reducing risk of cognitive decline and dementia July 21, 2016 brandi, roskamp institute 23
22 Other risk factors Education fewer years of education linked to increased risk of dementia Traumatic brain injury solid evidence to link to increased risk of dementia History of depression moderate link to increased risk of cognitive decline Sleep {Caregivers of family members with dementia} July 21, 2016 brandi, roskamp institute 24
23 Summary Research regarding neurocognitive diseases is promising but has a long way to go However, YOU CAN reduce your risk now! July 21, 2016 brandi, roskamp institute 25
24 and in conclusion.. July 21, 2016 brandi, roskamp institute 26
25 Roskamp Institute Roskamp Institute 2040 Whitfield Ave. Sarasota, FL Phone: Roskamp Institute Clinic Phone: July 21, 2016 brandi, roskamp institute 27
PUBLIC POLICIES AND ALZHEIMER RESEARCH
PUBLIC POLICIES AND ALZHEIMER RESEARCH 25TH ALHEIMER EUROPE CONFERENCE SEPTEMBER 2015 INTRODUCTION France Alzheimer and related diseases has, since its creation, put research at the center of its priorities
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationBGS Spring Risk Factors and Preventative Strategies for Dementia
Risk Factors and Preventative Strategies for Dementia Dr Blossom Stephan Senior Lecturer (in Risk Prediction) Newcastle University Institute for Ageing and Institute of Health and Society BGS Spring Meeting
More informationThe ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.
HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More information11/5/2018. Alzheimer s Disease Working Group: An Update. Learning Objectives. Facts & Figures
Alzheimer s Disease Working Group: An Update Learning Objectives Learn why early detection, diagnosis, and connections to resources are important. Understand the key recommendations from the 2011 Alzheimer
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationDementia prevention in the 21 st century
Dementia prevention in the 21 st century Stina Saunders, MRes 10 th Scottish Caring & Dementia Congress April 2018 Dementia rates In the UK, one person every three minutes develops dementia that is 1 in
More informationyears Towards a world without dementia
years 1 9 0 6-2 0 0 6 Towards a world without dementia A message from our patron A rewarding part of my public life has been my association with Alzheimer s Australia. During the National Consumer Summit
More informationAlzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What do we know about dementia and Alzheimer s disease? Alzheimer s disease is the most common form of dementia. Alzheimer s disease causes symptoms of
More information100 billion neurons!
100 billion neurons! Where s my car parked? Normal Memory Changes with Age Memory changes start even before 30 Harder to store new memories Sensory inputs aren't as sharp hear, see, taste Multi-tasking
More informationFinding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana
Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Bruce Lamb, Ph.D. Executive Director Stark Neurosciences Research Institute September 13, 2017 Critical
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationImproving Dementia Services in Northern Ireland. A Regional Strategy
Improving Dementia Services in Northern Ireland A Regional Strategy Contents 01. Introduction 02. Helpful words 04. About the strategy 05. Why dementia is an important condition 06. The impact of dementia
More informationAlzheimer s Disease Research
PRA INSIGHTS REPORT Alzheimer s Disease Research JULY 2017 Page 01 of 9 TABLE OF CONTENTS Introduction Methodology Summary Question One: Demographics Question Two: The Foremost Challenge in Neuroscience
More informationFROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018
FOR IMMEDIATE RELEASE CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, nfrantz@alz.org FROM THE ALZHEIMER S ASSOCIATION
More informationWhat is dementia. with Lewy bodies?
What is dementia with Lewy bodies? Contents 03 What is dementia with Lewy bodies? 04 Symptoms 05 Diagnosis 06 Treatments Information in this booklet is for anyone who wants to know more about dementia
More informationMEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH
MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH Nicci Kobritz, President Center for Brain Health & Youthful Aging Home Health 1 Our Goal Reduce the impact of modifiable medical risk factors associated
More informationAlzheimer s disease is an
Alzheimer s Disease FACT SHEET Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More information2018 Candidate Guide. Leading in the fight to end Alzheimer's
2018 Candidate Guide Leading in the fight to end Alzheimer's Table of Contents Candidate Letter...2 2018 Alzheimer's Disease Facts and Figures...3 Federal Policies to Lead on Alzheimer's...4 State Policies
More informationParkinson s Research Program
Parkinson s Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and the public
More informationPrioritizing Disease Prevention. Man and women, young and old, black and white, gay and straight, rich and poor,
El-Magbri 1 Prioritizing Disease Prevention Man and women, young and old, black and white, gay and straight, rich and poor, all are susceptible. Over 35 million are inflicted and the lives of far too many
More informationCAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA?
CAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA? Changes in Government Policy The Government has terminated the Dementia Initiative and risks squandering 6 years of investment. The Dementia Initiative
More informationSUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT
SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT Parkinson s disease (PD) affects an estimated 750,000 to 1 million Americans. Currently, there is no treatment to slow, stop
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationMentis Cura November
Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million
More informationPeer Reviewed Alzheimer s Research Program (PRARP)
Peer Reviewed Alzheimer s Research Program (PRARP) Col Wanda L. Salzer, USAF Director, CDMRP Anthony Pacifico, Ph.D. Program Manager, PRARP Disclaimer The information in this presentation is the opinion
More informationInvestor Update. Downloads. Services PDF. Basel, 17 July 2017
Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationStrategies for Dementia and Alzheimer s Care. Welcome and Introduction. Thank you, Why this topic? 3/9/2017
Strategies for Dementia and Alzheimer s Care LEADERS 2017 SLIDES PREPARED FOR PREVIEW MARCH CAMILLE PAVY CLAIBOURNE, APRN, PHD. Welcome and Introduction STRATEGIES CARING AND COMMUNICATING IN CAREGIVING
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationMolecular Imaging and the Brain
Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important
More informationALZHEIMER S ASSOCIATION
ALZHEIMER S ASSOCIATION Our mission: To eliminate Alzheimer s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through
More informationThere For You. Your Compassionate Guide. World-Class Hospice Care Since 1979
There For You Your Compassionate Guide World-Class Hospice Care Since 1979 What Is Hospice? Hospice is a type of care designed to provide support during an advanced illness. Hospice care focuses on comfort
More informationVascular and Degenerative Causes of Cognitive Impairment: How are they linked?
Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? MCI Symposium, Public Education Forum Presented by: Rebecca Gottesman, MD PhD January 20, 2019 1 Disclosures I am an Associate
More informationUnderstanding Clinical Trials
An excerpt from: Understanding Clinical Trials What is a clinical trial? Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research
More informationWorking with Your. Neurologist
Working with Your Neurologist What Is a Neurologist? A neurologist is a medical doctor with specialized training in diagnosing, treating, and managing disorders of the brain and nervous system. Neurologists
More informationShaping the Future of Dementia Care. Cheryl Miller, Phoebe Ministries Staff Development Coordinator
Shaping the Future of Dementia Care Cheryl Miller, Phoebe Ministries Staff Development Coordinator Objectives By the end of this session attendees will be able to: 1. List three modifiable risk factors
More informationCHRONIC CONDITIONS FYI
CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. ALS (Amyotrophic Lateral Sclerosis) Approximately 95 people in Nebraska have ALS. As many as 800 Nebraskans
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationCHRONIC CONDITIONS FYI
CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. Nationwide, this number is more than 1.2 million. ALS (Amyotrophic Lateral Sclerosis) There are 87 people
More informationPeer Reviewed Alzheimer s Research Program
Peer Reviewed Alzheimer s Research Program US Army Medical Research and Materiel Command Congressionally Directed Medical Research Programs HISTORY The Congressionally Directed Medical Research Programs
More information2017 ALZHEIMER'S DISEASE FACTS AND FIGURES
Page 1 of 5 2017 ALZHEIMER'S DISEASE FACTS AND FIGURES By Diana Iuliano-Chan, Region IV NARFE-Alzheimer's Regional Coordinator. The number of Americans living with Alzheimer's disease is growing and growing
More informationNew Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International Conference
Media Contacts: David Patti JFK Communications dpatti@jfkhealth.com (609) 241-7365 New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International
More informationResearch ALZHEIMER S DISEASE AND RISK FACTORS
Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the
More informationALZHEIMER'S DISEASE PREVENTION TRIALS
ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationMedical and scientific advances in prevention and treatment of dementia
Medical and scientific advances in prevention and treatment of dementia 12 th UK Dementia Congress Doncaster Prof Craig Ritchie Centre for Dementia Prevention Centre for Clinical Brain Sciences University
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationCARE CAMPUS EIT Health Hearing. CARE CAMPUS Caring and Ageing Reimagined in Europe. October 11 th, 2017
EIT Health Hearing Caring and Ageing Reimagined in Europe October 11 th, 2017 MISSION EIT Health accelerate entrepreneurship and innovation in healthy living and active ageing. Population Ageing is a global
More informationDietary Supplements, Caffeine, and Cognitive Aging
Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging
More informationRestoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.
Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which
More informationUNDERSTANDING ALZHEIMER S AND DEMENTIA
UNDERSTANDING ALZHEIMER S AND DEMENTIA Geri T., living with Alzheimer's, and her husband and care partner, Jim T. THE IMPACT OF ALZHEIMER S AND DEMENTIA Currently, an estimated 50 million people worldwide
More informationUnderstanding. Alzheimer s Disease. Lora, diagnosed in 2004, with her daughter, Jill.
Understanding Alzheimer s Disease Lora, diagnosed in 2004, with her daughter, Jill. What Is Alzheimer s Disease? Alzheimer s disease is a neurologic disorder that affects the brain. It causes dementia.
More informationFeatured Topic: Alzheimer s (5 slides)
Featured Topic: Alzheimer s (5 slides) The Rise of Alzheimer s Disease Mild memory problem: where did I put my car keys? Alzheimer s: what am I supposed to do with these keys? Scary Statistics: Between
More informationUCLA Alzheimer s and Dementia Care: Comprehensive, Coordinated, Patient-Centered
UCLA Alzheimer s and Dementia Care: Comprehensive, Coordinated, Patient-Centered David Geffen School of Medicine at UCLA Director: David B. Reuben, MD Medical Director: Zaldy S. Tan, MD, MPH Lead Dementia
More informationAlzheimer s: Our Next Public Health Success Story. John Shean, MPH Associate Director, Public Health Alzheimer s Association
Alzheimer s: Our Next Public Health Success Story John Shean, MPH Associate Director, Public Health Alzheimer s Association What is Public Health? What is Public Health? People Communities 3 What is Public
More informationAdvances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017
Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide
More informationGetting to Know the Generation Program s Approach to Disclosing Information about Your Risk for Alzheimer s disease
Getting to Know the Generation Program s Approach to Disclosing Information about Your Risk for Alzheimer s disease The Generation Program is made up of two clinical trials: Generation Study 1 and Generation
More informationSixth Annual Seattle Hope Gala
American Cancer Society Sixth Annual Seattle Hope Gala The Facts Event Information The American Cancer Society sixth annual Seattle Hope Gala will be held on Saturday, October 11, 2014, at Fremont Studios
More information1 in 3 seniors dies with Alzheimer s or another dementia.
2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers
More informationSPONSORSHIP OPPORTUNITIES
SPONSORSHIP OPPORTUNITIES 2018 WHAT IS HYDROCEPHALUS? Hydrocephalus is caused by an imbalance in the production and absorption of cerebral spinal fluid in the brain which causes the ventricles to enlarge.
More informationBuilding Quality Into Outpatient Dementia Care For Mainers
Building Quality Into Outpatient Dementia Care For Mainers Cliff Singer MD Chief, Geriatric Mental Health and Neuropsychiatry Principal Investigator, Alzheimer s Disease Clinical Research Program Acadia
More informationConsultation on Australian Medical Research and Innovation Priorities for
Australian Medical Research Advisory Board Consultation on Australian Medical Research and Innovation Priorities for 2018-2021 Submission from Dementia Australia July 2018 1 About Dementia Australia Dementia
More informationAlzheimer s Association: Public Health Perspectives & Initiatives
Alzheimer s Association: Public Health Perspectives & Initiatives Maria C. Carrillo, Ph.D. Chief Science Officer Disclosures: Full time employee of the Alzheimer s Association 2 Outline Prevalence vs Incidence
More informationComments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967
Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967 The American Lung Association welcomes the opportunity to comment on the
More informationContents. Introduction. Introduction 03
Genes and dementia Introduction This information is for anyone who wants to know more about the link between genes and dementia. This includes people living with dementia, their carers, friends and families.
More informationExploring Outcomes and Value across the Spectrum of Alzheimer s Disease Pennsylvania Avenue NW, Washington, DC June 20, 2017
Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease 1201 Pennsylvania Avenue NW, Washington, DC 20004 June 20, 2017 Meeting Summary Meeting Objectives Alzheimer s disease (AD) has a
More informationDISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY. Presented by Rob Parke Lalit Baveja
DISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY CARE Presented by Rob Parke Lalit Baveja Jaiwardhan Vij February 12-13, 13 2009 Agenda India s s Chronic Disease Burden Overview of Disease
More informationTreatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK
Treatments of tomorrow: dementia research and drug discovery Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK More failure What is different about dementia drug discovery? The
More informationAmerican Cancer Society
American Cancer Society Breast Cancer Awareness for the Worksite HAP Worksite Wellness Forum October 18,2012 Melissa DiPirro Coordinator, Health Initiatives Official Sponsor of Birthdays Mission: We are
More informationour vision our mission 7/24/18 Twin Ports Conference Session 202 Learning Objectives
Twin Ports Conference Session 202 Memory Loss and Dementia: An African American and Health Euity Lens Alzheimer s Association: Robbin Frazier, Director of Diversity and Inclusion E-mail: rfrazier@alz.org
More informationDementia and cognitive decline
Dementia and cognitive decline Expert Briefing Su Ray and Dr Susan Davidson Research Department Together, we can help everyone to love later life 01 Brain basics Normal ageing, cognitive impairment and
More informationAlzheimer s disease Dispelling the myths
Alzheimer s disease Dispelling the myths Myth and Reality Over the years, many myths have evolved about what Alzheimer s disease is, who gets it and how it affects people who have it. These myths can add
More informationChronic Effects of Neurotrauma Consortium (CENC)
Chronic Effects of Neurotrauma Consortium (CENC) 2013-2019 David X. Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Associate Dean for Innovation and System Integrations, Virginia Commonwealth
More informationPfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationRanking Nutritional Supplements Botanical Medicine Primary
Your Monthly Update Dear Colleague Welcome to the October newsletter from Pure Bio Ltd. Did you know...? The UK organic market grew by 30% and averaged sales of 7million a week in 2005! Our topic for this
More informationreverse parkinsons BAD27E3FE044E25F3F8EBDA3B54333A9 Reverse Parkinsons 1 / 6
Reverse Parkinsons 1 / 6 2 / 6 3 / 6 Reverse Parkinsons Reverse Parkinson's Disease!-Take back your life! Do you want to improve your quality of life, when you have Parkinson's disease? Contrary to the
More informationClinical Research Studies at Johns Hopkins Bayview. Frequently Asked Questions
Clinical Research Studies at Johns Hopkins Bayview Frequently Asked Questions Without clinical research, progress in improving health and treatment of disease would not be possible. To achieve success,
More informationNational Plan to Address Alzheimer s Disease
National Plan to Address Alzheimer s Disease On May 15, 2012, the Obama Administration released our country s first-ever National Alzheimer s Plan. What is this plan? Why is it needed? And how will it
More informationYour legacy. Their cure. The Brain Tissue Resource Facility
Your legacy. Their cure. The Brain Tissue Resource Facility Your donation offers future generations the hope of a cure. An introduction to brain tissue donation and the autopsy assistance program One of
More information2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES
2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES WHAT IS HYDROCEPHALUS? Hydrocephalus is caused by an imbalance in the production and absorption of cerebral spinal fluid in the
More informationThe summit and its purpose
Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to
More informationMASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER
MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More informationThe Special Diabetes Program
The Special Diabetes Program Advancing Research & Improving Lives on the Path to a Cure Charlie was diagnosed with T1D at 10 months old. Some days, he wants to be a doctor when he grows up. Other days,
More informationThe REACH Caregiver Intervention Program: From Clinical Trial to Community Implementation. HRJ Endowed Chair University of Michigan
The REACH Caregiver Intervention Program: From Clinical Trial to Community Implementation Lou Burgio, Ph.D. HRJ Endowed Chair University of Michigan Background dementia (Facts and Figures, Alzheimer s
More informationDementia DR UMAR BEDI CONSULTANT-OLD AGE PSYCHIATRY 10/1/2018 1
Dementia DR UMAR BEDI CONSULTANT-OLD AGE PSYCHIATRY 10/1/2018 1 TOPICS FOR DISCUSSION Man- FETCH Wife- THE DOG DIED 2 YEARS AGO HENRY 10/1/2018 2 TOPICS FOR DISCUSSION Dementia news What is Dementia? Why
More informationClinical Trials: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Clinical Trials: Questions
More informationPROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS
PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is
More informationNational Survivorship and QoL Research:
National Survivorship and QoL Research: Impact on Interventions, Guidelines, and Resources Kevin D. Stein, PhD, Vice President, Behavioral Research, Director, Behavioral Research Center, American Cancer
More information